Pre-rev­enue vac­cine de­vel­op­er CanSi­no lines up at a buzzing HKEX

On the same day As­cle­tis start­ed pub­licly pitch­ing its his­toric IPO on the Hong Kong stock ex­change, an­oth­er home­grown drug­mak­er is tak­ing its own shot at a pub­lic list­ing.

Prob­a­bly best known for its Ebo­la vac­cine — which got ap­proved and ac­cept­ed in­to Chi­na’s na­tion­al stock­pile last Oc­to­ber — CanSi­no Bi­o­log­ics is de­vel­op­ing 15 vac­cine can­di­dates for 12 dis­ease ar­eas in to­tal. The lead pro­grams fo­cus on meningo­coc­cal con­ju­gate vac­cines, fol­lowed by ver­sions of the com­mon DTP vac­cine, both of which would be boost­ed by the raise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER